Burning Rock Biotech (NASDAQ:BNR) Issues Quarterly Earnings Results

Key Points

• Burning Rock Biotech reported a negative earnings per share (EPS) of ($0.15) for the quarter, reflecting significant financial challenges with a negative return on equity of 38.33% and a negative net margin of 45.41%.
• The stock is currently valued at $8.30, with a market capitalization of $89.25 million and a price-to-earnings (P/E) ratio of -4.39, indicating the company is operating at a loss.
• Burning Rock Biotech specializes in next-generation sequencing based cancer therapy selection tests, targeting various cancer types through tissue and liquid biopsy samples.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, Zacks reports. Burning Rock Biotech had a negative net margin of 26.04% and a negative return on equity of 23.61%. The business had revenue of $20.74 million during the quarter.

Burning Rock Biotech Trading Down 3.6%

Shares of BNR traded down $0.32 during mid-day trading on Friday, reaching $8.49. The company's stock had a trading volume of 24,345 shares, compared to its average volume of 51,006. Burning Rock Biotech has a 1-year low of $2.18 and a 1-year high of $11.12. The stock has a market cap of $91.37 million, a P/E ratio of -4.47 and a beta of 0.91. The business has a 50-day simple moving average of $7.03 and a two-hundred day simple moving average of $4.86.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.